Relationship between interleukin-6, coronary artery calcium and risk of heart failure: Insights from MESA.

Ahmad MI, Chevli PA, Mirzai S, Rikhi R, Pagidipati N, Slipczuk L, Szklo M, Shapiro MD

Aspirin and Lipoprotein(a): Lessons from Replication at Scale.

Shapiro MD, Ruscica M

Untreated Hypertension and Diabetes in the Chest Pain Observation Unit.

Hutchison BT, Ashburn NP, Snavely AC, Shapiro MD, Chado MA, Ambrosini AP, Biglari AA, Cannon HA, Millard MJ, Dameron AG, Mahler SA

Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial.

Geba GP, Mohammadi KA, Damask A, Paulding C, Lotta LA, Hindy G, Pordy R, Manvelian G, Shapiro MD, Bittner VA, Bhatt DL, Szarek M, Schwartz GG, Steg PG, Fazio S

APOC3 inhibition: The strongest case yet for triglyceride targeting.

Shapiro MD, Slipczuk L

Bridging the inflammation gap by IL-6 inhibition.

Shapiro MD

Initiating Preventive Care for Hyperlipidemia in the Emergency Department: The Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial.

Ashburn NP, Snavely AC, Ehrig MR, Shapiro MD, Herrington DM, Reboussin DM, Gesell SB, Mahler SA

Impact of a Meds-to-Beds PCSK9i Initiation Program on LDL-C in Patients Undergoing ASCVD Revascularization.

Lorenzatti D, Greenberg GS, Filtz A, Scotti A, Jaspan VN, Park CM, Kalich B, Jones LK, Kathe N, Di Palo KE, Browne C, Lipsitz E, Forest SJ, Latib A, Garcia MJ, Rodriguez CJ, Shapiro MD, Gulati M, Slipczuk L

Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications.

Razavi AC, Bhatia HS, Blumenthal RS, Shapiro MD, Mehta A

Atherogenic dyslipidemia and incident cardiovascular events in high-risk hypertension.

Kazibwe R, Jehopio J, Schaich CL, Rikhi R, Mirzai S, Chevli PA, Namutebi JH, Chebrolu S, O'Connor S, Yeboah J, Shapiro MD